The latest price target for Entrada Therapeutics (NASDAQ:TRDA) was reported by Roth MKM on December 5, 2024. The analyst firm set a price target for $29.00 expecting TRDA to rise to within 12 months (a possible 68.60% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Entrada Therapeutics (NASDAQ:TRDA) was provided by Roth MKM, and Entrada Therapeutics initiated their buy rating.

There is no last upgrade for Entrada Therapeutics

There is no last downgrade for Entrada Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entrada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entrada Therapeutics was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest Entrada Therapeutics (TRDA) rating was a initiated with a price target of $0.00 to $29.00. The current price Entrada Therapeutics (TRDA) is trading at is $17.20, which is within the analyst’s predicted range.